"Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: A result of treatment success, not failure

Medical Journal of Australia

Volumn 191, Issue 10, 2009, Pages 564-566

  O'Brien, Daniel P ^a,b   Robson, Michael E ^c   Callan, Peter P ^a   McDonald, Anthony H ^a  

^a BARWON HEALTH   (Australia)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c Department of Anatomical Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CIPROFLOXACIN; CLARITHROMYCIN; RIFAMPICIN; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN;

ADULT; AGED; ARTICLE; BURULI ULCER; CASE REPORT; DETERIORATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MYCOBACTERIUM ULCERANS; SKIN EDEMA; SKIN INDURATION; SKIN INFLAMMATION; SKIN NECROSIS; SPLIT THICKNESS SKIN GRAFT; SUBCUTANEOUS TISSUE; WOUND CLOSURE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BURULI ULCER; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; TREATMENT OUTCOME;

EID: 76749086213     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb03313.x     Document Type: Article

References (12)

1. Schutte D, Umboock A, Pluschke G. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 2009; 160: 273-283.
2. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006; 19: 20-25. (Pubitemid 43032435)
3. Carvalho AC, De Iaco G, Saleri N, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 2006; 42: 893-895. (Pubitemid 43363957)
4. Guarner J, Bartlett J, Whitney EA, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003; 9: 651-656. (Pubitemid 36676359)
5. Adusumilli S, Mve-Obiang A, Sparer T, et al. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 2005; 7: 1295-1304. (Pubitemid 41179422)
6. Coutanceau E, Decalf J, Martino A, et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 2007; 204: 1395-1403. (Pubitemid 46919877)
7. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61.
8. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51: 4029-4035. (Pubitemid 350057802)
9. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease. Geneva: WHO, 2004.
10. Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68.
11. Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 2005; 40: 1368-1371. (Pubitemid 40570251)
12. Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-759.